MA-ECHOSENS
15.11.2021 14:58:06 CET | Business Wire | Press release
Echosens , a high-technology company offering the FibroScan® family of products, recognizes the importance of World Diabetes Day (WDD), Nov. 14 and the month of November as American Diabetes Month for bringing greater focus to the impact of Type 2 diabetes and its link to metabolic syndrome (MetS) and nonalcoholic fatty liver disease (NAFLD). MetS is a cluster of risk factors specific for cardiovascular disease, and NAFLD is the accumulation of liver fat in people who drink little or no alcohol. Obesity is the most frequently observed component of MetS.
“WWD, a three-year campaign to improve access to diabetes care and prevent diabetes, and the American Diabetes Month present opportunities to highlight how obesity increases the risk for Type 2 diabetes, liver disease, MetS and heart disease,” says Dominique Legros, Echosens Group CEO. “Fat in the liver can increase the risks of progression of prediabetes to overt disease. Once a patient has fatty liver disease, diabetes may become more difficult to control, making it critical to obtain an early diagnosis and introduce lifestyle changes to halt or reverse NAFLD.”
NAFLD has 70% prevalence among Type 2 diabetes patients, and people living with Type 2 diabetes and NAFLD are at a two-fold risk of all-cause mortality versus those living with Type 2 diabetes alone. In the United States, 36.5% of adults are obese, while another 32.5% of American adults are overweight. Globally, about 13% of the world’s adult population has obesity and about 39% are overweight, according to the World Health Organization’s most recent statistics.
FibroScan, a painless, non-invasive exam at the point of care can measure and monitor the amount of liver stiffness and detect NAFLD in its earliest stages when the individual may be asymptomatic. It can be used to rule out the need for further assessment, such as a painful liver biopsy, saving time and resources for people who don’t need further assessment.
“The good news is that even moderate weight loss can significantly reduce liver fat in patients with NAFLD and play an essential role in the prevention and treatment of Type 2 diabetes,” adds Dominique Legros. “This November, we urge everyone touched by the growing liver disease epidemic to help promote advocacy efforts throughout the year and confront diabetes as a critical global health issue.”
To learn more, read “Early Detection, Healthy Diet and Lifestyle Changes Critical for Addressing Metabolic Syndrome and Halting Progression of Liver Disease .”
About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan® , the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,000 peer reviewed publications and 140+ international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005001/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release
€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom